Pegcrisantaspase clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses pegcrisantaspase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Jazz Pharmaceuticals (2) · University of Maryland, Baltimore (1) · M.D. Anderson Cancer Center (1)
Studies
Open first, then newest update. How each study uses pegcrisantaspase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)CompletedPhase 1University of Maryland, BaltimoreNCT04666649Written as Venetoclax and pegcrisantaspase
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedPhase 1M.D. Anderson Cancer CenterNCT04526795Written as Pegcrisantaspase
- A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)TerminatedPhase 2Jazz PharmaceuticalsNCT02257684Written as pegcrisantaspase
- Phase I Study of mPEG-R-Crisantaspase Given IVCompletedPhase 1Jazz PharmaceuticalsNCT01551524Written as mPEG-r-crisantaspase
Codes
What other systems call pegcrisantaspase · ClinicalTrials.gg INT018568
- UNII (FDA) Y8KTZ6Y35UPEGCRISANTASPASEOne source FDA
- NCI Thesaurus C170297PegcrisantaspaseOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y8KTZ6Y35U | PEGCRISANTASPASE | One source FDA |
| NCI Thesaurus | C170297 | Pegcrisantaspase | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.